HomeBUSINESS
BUSINESS

Biogen Enters Exclusive Option Agreement for Acute Stroke Treatment with Japanese Biotech
(Jun.12.2018)

Biogen has announced that it has entered into an exclusive option agreement with Japanese biotech TMS Co. Ltd. to acquire the acute stroke treatment TMS-007 and backup compounds. The company aims to strengthen its portfolio for stroke, one of its core fields ...
(LOG IN FOR FULL STORY)